Global PD-L1 Biomarker Testing Market Growth (Status and Outlook) 2025-2031

August 2025 | 81 pages | ID: G6BB1BF98D86EN
LP Information

Abstracts

According to this study, the global PD-L1 Biomarker Testing market size will reach US$ 28130 million by 2031.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to 'trick' the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The PD-L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD-1/PD-L1 axis, which have shown remarkable clinical success in treating various advanced cancers—spurring widespread demand for stratifying patients based on PD-L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD-L1 testing to guide therapeutic decisions and enable companion diagnostics—especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis .

Despite these positive trends, the PD-L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19–32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

LPI (LP Information)' newest research report, the “PD-L1 Biomarker Testing Industry Forecast” looks at past sales and reviews total world PD-L1 Biomarker Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-L1 Biomarker Testing sales for 2025 through 2031. With PD-L1 Biomarker Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-L1 Biomarker Testing industry.

This Insight Report provides a comprehensive analysis of the global PD-L1 Biomarker Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-L1 Biomarker Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-L1 Biomarker Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-L1 Biomarker Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-L1 Biomarker Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of PD-L1 Biomarker Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:

• PD-L1 (22C3)
• PD-L1(28-8)
• PD-L1 (SP142)
• PD-L1 (SP263)
• Other

Segmentation by Application:

• Hospital
• Diagnostic Center
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Agilent Technologies
• Roche
• Merck
• Bristol-Myers Squibb
• AstraZeneca
• Ono Pharmaceutical
• Regeneron
• Innovent
• Hengrui Medicine
• Junshi Biosciences

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global PD-L1 Biomarker Testing Market Size (2020-2031)
  2.1.2 PD-L1 Biomarker Testing Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for PD-L1 Biomarker Testing by Country/Region (2020, 2024 & 2031)
2.2 PD-L1 Biomarker Testing Segment by Type
  2.2.1 PD-L1 (22C3)
  2.2.2 PD-L1(28-8)
  2.2.3 PD-L1 (SP142)
  2.2.4 PD-L1 (SP263)
  2.2.5 Other
2.3 PD-L1 Biomarker Testing Market Size by Type
  2.3.1 PD-L1 Biomarker Testing Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
2.4 PD-L1 Biomarker Testing Segment by Application
  2.4.1 Hospital
  2.4.2 Diagnostic Center
  2.4.3 Others
2.5 PD-L1 Biomarker Testing Market Size by Application
  2.5.1 PD-L1 Biomarker Testing Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)

3 PD-L1 BIOMARKER TESTING MARKET SIZE BY PLAYER

3.1 PD-L1 Biomarker Testing Market Size Market Share by Player
  3.1.1 Global PD-L1 Biomarker Testing Revenue by Player (2020-2025)
  3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Player (2020-2025)
3.2 Global PD-L1 Biomarker Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 PD-L1 BIOMARKER TESTING BY REGION

4.1 PD-L1 Biomarker Testing Market Size by Region (2020-2025)
4.2 Global PD-L1 Biomarker Testing Annual Revenue by Country/Region (2020-2025)
4.3 Americas PD-L1 Biomarker Testing Market Size Growth (2020-2025)
4.4 APAC PD-L1 Biomarker Testing Market Size Growth (2020-2025)
4.5 Europe PD-L1 Biomarker Testing Market Size Growth (2020-2025)
4.6 Middle East & Africa PD-L1 Biomarker Testing Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas PD-L1 Biomarker Testing Market Size by Country (2020-2025)
5.2 Americas PD-L1 Biomarker Testing Market Size by Type (2020-2025)
5.3 Americas PD-L1 Biomarker Testing Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC PD-L1 Biomarker Testing Market Size by Region (2020-2025)
6.2 APAC PD-L1 Biomarker Testing Market Size by Type (2020-2025)
6.3 APAC PD-L1 Biomarker Testing Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025)
7.2 Europe PD-L1 Biomarker Testing Market Size by Type (2020-2025)
7.3 Europe PD-L1 Biomarker Testing Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa PD-L1 Biomarker Testing by Region (2020-2025)
8.2 Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2020-2025)
8.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL PD-L1 BIOMARKER TESTING MARKET FORECAST

10.1 Global PD-L1 Biomarker Testing Forecast by Region (2026-2031)
  10.1.1 Global PD-L1 Biomarker Testing Forecast by Region (2026-2031)
  10.1.2 Americas PD-L1 Biomarker Testing Forecast
  10.1.3 APAC PD-L1 Biomarker Testing Forecast
  10.1.4 Europe PD-L1 Biomarker Testing Forecast
  10.1.5 Middle East & Africa PD-L1 Biomarker Testing Forecast
10.2 Americas PD-L1 Biomarker Testing Forecast by Country (2026-2031)
  10.2.1 United States Market PD-L1 Biomarker Testing Forecast
  10.2.2 Canada Market PD-L1 Biomarker Testing Forecast
  10.2.3 Mexico Market PD-L1 Biomarker Testing Forecast
  10.2.4 Brazil Market PD-L1 Biomarker Testing Forecast
10.3 APAC PD-L1 Biomarker Testing Forecast by Region (2026-2031)
  10.3.1 China PD-L1 Biomarker Testing Market Forecast
  10.3.2 Japan Market PD-L1 Biomarker Testing Forecast
  10.3.3 Korea Market PD-L1 Biomarker Testing Forecast
  10.3.4 Southeast Asia Market PD-L1 Biomarker Testing Forecast
  10.3.5 India Market PD-L1 Biomarker Testing Forecast
  10.3.6 Australia Market PD-L1 Biomarker Testing Forecast
10.4 Europe PD-L1 Biomarker Testing Forecast by Country (2026-2031)
  10.4.1 Germany Market PD-L1 Biomarker Testing Forecast
  10.4.2 France Market PD-L1 Biomarker Testing Forecast
  10.4.3 UK Market PD-L1 Biomarker Testing Forecast
  10.4.4 Italy Market PD-L1 Biomarker Testing Forecast
  10.4.5 Russia Market PD-L1 Biomarker Testing Forecast
10.5 Middle East & Africa PD-L1 Biomarker Testing Forecast by Region (2026-2031)
  10.5.1 Egypt Market PD-L1 Biomarker Testing Forecast
  10.5.2 South Africa Market PD-L1 Biomarker Testing Forecast
  10.5.3 Israel Market PD-L1 Biomarker Testing Forecast
  10.5.4 Turkey Market PD-L1 Biomarker Testing Forecast
10.6 Global PD-L1 Biomarker Testing Forecast by Type (2026-2031)
10.7 Global PD-L1 Biomarker Testing Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market PD-L1 Biomarker Testing Forecast

11 KEY PLAYERS ANALYSIS

11.1 Agilent Technologies
  11.1.1 Agilent Technologies Company Information
  11.1.2 Agilent Technologies PD-L1 Biomarker Testing Product Offered
  11.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Agilent Technologies Main Business Overview
  11.1.5 Agilent Technologies Latest Developments
11.2 Roche
  11.2.1 Roche Company Information
  11.2.2 Roche PD-L1 Biomarker Testing Product Offered
  11.2.3 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Roche Main Business Overview
  11.2.5 Roche Latest Developments
11.3 Merck
  11.3.1 Merck Company Information
  11.3.2 Merck PD-L1 Biomarker Testing Product Offered
  11.3.3 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Merck Main Business Overview
  11.3.5 Merck Latest Developments
11.4 Bristol-Myers Squibb
  11.4.1 Bristol-Myers Squibb Company Information
  11.4.2 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Offered
  11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Bristol-Myers Squibb Main Business Overview
  11.4.5 Bristol-Myers Squibb Latest Developments
11.5 AstraZeneca
  11.5.1 AstraZeneca Company Information
  11.5.2 AstraZeneca PD-L1 Biomarker Testing Product Offered
  11.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 AstraZeneca Main Business Overview
  11.5.5 AstraZeneca Latest Developments
11.6 Ono Pharmaceutical
  11.6.1 Ono Pharmaceutical Company Information
  11.6.2 Ono Pharmaceutical PD-L1 Biomarker Testing Product Offered
  11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Ono Pharmaceutical Main Business Overview
  11.6.5 Ono Pharmaceutical Latest Developments
11.7 Regeneron
  11.7.1 Regeneron Company Information
  11.7.2 Regeneron PD-L1 Biomarker Testing Product Offered
  11.7.3 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Regeneron Main Business Overview
  11.7.5 Regeneron Latest Developments
11.8 Innovent
  11.8.1 Innovent Company Information
  11.8.2 Innovent PD-L1 Biomarker Testing Product Offered
  11.8.3 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Innovent Main Business Overview
  11.8.5 Innovent Latest Developments
11.9 Hengrui Medicine
  11.9.1 Hengrui Medicine Company Information
  11.9.2 Hengrui Medicine PD-L1 Biomarker Testing Product Offered
  11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 Hengrui Medicine Main Business Overview
  11.9.5 Hengrui Medicine Latest Developments
11.10 Junshi Biosciences
  11.10.1 Junshi Biosciences Company Information
  11.10.2 Junshi Biosciences PD-L1 Biomarker Testing Product Offered
  11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Junshi Biosciences Main Business Overview
  11.10.5 Junshi Biosciences Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. PD-L1 Biomarker Testing Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. PD-L1 Biomarker Testing Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of PD-L1 (22C3)
Table 4. Major Players of PD-L1(28-8)
Table 5. Major Players of PD-L1 (SP142)
Table 6. Major Players of PD-L1 (SP263)
Table 7. Major Players of Other
Table 8. PD-L1 Biomarker Testing Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global PD-L1 Biomarker Testing Market Size by Type (2020-2025) & ($ millions)
Table 10. Global PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
Table 11. PD-L1 Biomarker Testing Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global PD-L1 Biomarker Testing Market Size by Application (2020-2025) & ($ millions)
Table 13. Global PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)
Table 14. Global PD-L1 Biomarker Testing Revenue by Player (2020-2025) & ($ millions)
Table 15. Global PD-L1 Biomarker Testing Revenue Market Share by Player (2020-2025)
Table 16. PD-L1 Biomarker Testing Key Players Head office and Products Offered
Table 17. PD-L1 Biomarker Testing Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global PD-L1 Biomarker Testing Market Size by Region (2020-2025) & ($ millions)
Table 21. Global PD-L1 Biomarker Testing Market Size Market Share by Region (2020-2025)
Table 22. Global PD-L1 Biomarker Testing Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global PD-L1 Biomarker Testing Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas PD-L1 Biomarker Testing Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas PD-L1 Biomarker Testing Market Size Market Share by Country (2020-2025)
Table 26. Americas PD-L1 Biomarker Testing Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
Table 28. Americas PD-L1 Biomarker Testing Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)
Table 30. APAC PD-L1 Biomarker Testing Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC PD-L1 Biomarker Testing Market Size Market Share by Region (2020-2025)
Table 32. APAC PD-L1 Biomarker Testing Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC PD-L1 Biomarker Testing Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe PD-L1 Biomarker Testing Market Size Market Share by Country (2020-2025)
Table 36. Europe PD-L1 Biomarker Testing Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe PD-L1 Biomarker Testing Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa PD-L1 Biomarker Testing Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of PD-L1 Biomarker Testing
Table 42. Key Market Challenges & Risks of PD-L1 Biomarker Testing
Table 43. Key Industry Trends of PD-L1 Biomarker Testing
Table 44. Global PD-L1 Biomarker Testing Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global PD-L1 Biomarker Testing Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global PD-L1 Biomarker Testing Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global PD-L1 Biomarker Testing Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Agilent Technologies Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 49. Agilent Technologies PD-L1 Biomarker Testing Product Offered
Table 50. Agilent Technologies PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Agilent Technologies Main Business
Table 52. Agilent Technologies Latest Developments
Table 53. Roche Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 54. Roche PD-L1 Biomarker Testing Product Offered
Table 55. Roche PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Roche Main Business
Table 57. Roche Latest Developments
Table 58. Merck Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 59. Merck PD-L1 Biomarker Testing Product Offered
Table 60. Merck PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Merck Main Business
Table 62. Merck Latest Developments
Table 63. Bristol-Myers Squibb Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 64. Bristol-Myers Squibb PD-L1 Biomarker Testing Product Offered
Table 65. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Bristol-Myers Squibb Main Business
Table 67. Bristol-Myers Squibb Latest Developments
Table 68. AstraZeneca Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 69. AstraZeneca PD-L1 Biomarker Testing Product Offered
Table 70. AstraZeneca PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. AstraZeneca Main Business
Table 72. AstraZeneca Latest Developments
Table 73. Ono Pharmaceutical Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 74. Ono Pharmaceutical PD-L1 Biomarker Testing Product Offered
Table 75. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. Ono Pharmaceutical Main Business
Table 77. Ono Pharmaceutical Latest Developments
Table 78. Regeneron Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 79. Regeneron PD-L1 Biomarker Testing Product Offered
Table 80. Regeneron PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. Regeneron Main Business
Table 82. Regeneron Latest Developments
Table 83. Innovent Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 84. Innovent PD-L1 Biomarker Testing Product Offered
Table 85. Innovent PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Innovent Main Business
Table 87. Innovent Latest Developments
Table 88. Hengrui Medicine Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 89. Hengrui Medicine PD-L1 Biomarker Testing Product Offered
Table 90. Hengrui Medicine PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. Hengrui Medicine Main Business
Table 92. Hengrui Medicine Latest Developments
Table 93. Junshi Biosciences Details, Company Type, PD-L1 Biomarker Testing Area Served and Its Competitors
Table 94. Junshi Biosciences PD-L1 Biomarker Testing Product Offered
Table 95. Junshi Biosciences PD-L1 Biomarker Testing Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. Junshi Biosciences Main Business
Table 97. Junshi Biosciences Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. PD-L1 Biomarker Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global PD-L1 Biomarker Testing Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. PD-L1 Biomarker Testing Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. PD-L1 Biomarker Testing Sales Market Share by Country/Region (2024)
Figure 8. PD-L1 Biomarker Testing Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global PD-L1 Biomarker Testing Market Size Market Share by Type in 2024
Figure 10. PD-L1 Biomarker Testing in Hospital
Figure 11. Global PD-L1 Biomarker Testing Market: Hospital (2020-2025) & ($ millions)
Figure 12. PD-L1 Biomarker Testing in Diagnostic Center
Figure 13. Global PD-L1 Biomarker Testing Market: Diagnostic Center (2020-2025) & ($ millions)
Figure 14. PD-L1 Biomarker Testing in Others
Figure 15. Global PD-L1 Biomarker Testing Market: Others (2020-2025) & ($ millions)
Figure 16. Global PD-L1 Biomarker Testing Market Size Market Share by Application in 2024
Figure 17. Global PD-L1 Biomarker Testing Revenue Market Share by Player in 2024
Figure 18. Global PD-L1 Biomarker Testing Market Size Market Share by Region (2020-2025)
Figure 19. Americas PD-L1 Biomarker Testing Market Size 2020-2025 ($ millions)
Figure 20. APAC PD-L1 Biomarker Testing Market Size 2020-2025 ($ millions)
Figure 21. Europe PD-L1 Biomarker Testing Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa PD-L1 Biomarker Testing Market Size 2020-2025 ($ millions)
Figure 23. Americas PD-L1 Biomarker Testing Value Market Share by Country in 2024
Figure 24. United States PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC PD-L1 Biomarker Testing Market Size Market Share by Region in 2024
Figure 29. APAC PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
Figure 30. APAC PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)
Figure 31. China PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 35. India PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe PD-L1 Biomarker Testing Market Size Market Share by Country in 2024
Figure 38. Europe PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
Figure 39. Europe PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)
Figure 40. Germany PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 41. France PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 42. UK PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa PD-L1 Biomarker Testing Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa PD-L1 Biomarker Testing Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa PD-L1 Biomarker Testing Market Size Market Share by Application (2020-2025)
Figure 48. Egypt PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries PD-L1 Biomarker Testing Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 54. APAC PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 55. Europe PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 57. United States PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 58. Canada PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 59. Mexico PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 60. Brazil PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 61. China PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 62. Japan PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 63. Korea PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 65. India PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 66. Australia PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 67. Germany PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 68. France PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 69. UK PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 70. Italy PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 71. Russia PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 72. Egypt PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 73. South Africa PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 74. Israel PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 75. Turkey PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)
Figure 76. Global PD-L1 Biomarker Testing Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global PD-L1 Biomarker Testing Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries PD-L1 Biomarker Testing Market Size 2026-2031 ($ millions)